The art of forecasting and the impact of forecasts: The case of chronic hepatitis CChronic hepatitis C is often depicted by the media as the “silent killer”. This definition is appropriate for a disease that is symptomless for years or even decades, during which it can be identified only by detecting anti-hepatitis C virus (HCV) antibodies in plasma and then confirmed by detecting HCV RNA. When the disease becomes clinically evident, the progression to cirrhosis or cancer has already occurred in many cases. At this stage, therapeutic opportunities are restricted, management is costly and life expectancy is low .
Introduction to Mini-Symposium on Cholangiocyte Pathophysiology—Part IIt is my great pleasure to present in this issue of Digestive and Liver Disease, Part I of the 2010 Mini-Symposium on Cholangiocyte Pathophysiology, for which I have gladly accepted the role of Guest Editor. For this collection of articles, the Editorial Board has invited an impressive line-up of renowned international experts to write comprehensive and up-to-date reviews on a wide range of topics centered on cholangiocyte proliferation, differentiation, and mechanisms of disease. To all the dedicated Authors whose efforts made this series possible I would like to extend the gratitude of the Editorial Board, and congratulate them for the outstanding quality of their manuscripts.